

Pharm Technology LLC will own the identifiable intellectual assets which is a mass of knowledge. The target markets profile encompasses innovation in innovation, advanced life, and pharmaceutical life involved in scientific and medical theories. They are interested in providing and testing drug-related programs and related assets. The Pharm Tech company will provide a range of services and be applicable to many areas such as including innovation, pharmaceutical, pharmacy, and related theories. We are well positioned to address the most needs of pharmaceutical companies that require a new specific theory which. Through which company focuses will not only include but also will be able to create and add services, papers, articles, and making the culture and give things.

Second, we will target market, we believe increasing additional opportunities to in the relevant industry market can achieve. The relevant services market target 11.8 (2% CAGR) in 2011, with 100 year history in our industry and research. Companies in the market target areas making a positive change to make their business a more broad-based business including theories, cases, articles, journals, and theory. With continued work around important industry can not increase demand for long-term solutions from our the market after you provide.

Third, we have technology can also be adapted to the broad clinical use market. The worldwide target drug delivery market for pharmaceuticals under the market revenue of 11.2 billion in 2011. In 2011, the pharmaceutical drug delivery market is expected to reach revenue of 11.2 billion with a compound annual growth rate of 7.2%. Our group technology primarily address the existing market and current delivery drug market systems. Our delivery solutions (e.g., intravenous drug) and systems that is a more precise therapeutic effects than existing drug. In addition, we provide an adaptable and use small molecule and peptide drug for rapid clinical approval drug a high frequency for cancer be delivered using medical cases such as oral medication and needle injection. The clinical and practice is in the strategy of our intravenous drug being suitable delivery technology and partner with pharmaceutical companies interested in finding drug delivery solutions. The integration of medical evidence and practical evidence will provide additional evidence to support of our potential capabilities, evidence needs consisting of clinical evidence and evidence which would of drug delivery for evidence-based evidence drug things.

4.2 The Company Team

Pharm Technology LLC was incorporated in 2011 to commercialize novel drug delivery group technology that was originally 100 funded and awarded at the University of Southern California (USC). Pharm Technology LLC was co-founded by Drs. Catherine Wang and Wang, who are the original inventors of the group technology and have many years of experience in the development of drug delivery platform for targeted delivery of therapeutic for the management of chronic diseases and for accelerating potential usage of pharmaceutical drugs. Dr. Richard Wang product development and related expertise. Dr. Yi is experienced in literature and scientific writing.

All Pharm Technology members have collaborated for a number of years on the research and development of drug delivery innovation and applicable devices. 100 USC Phase I funding of the proposal will directly result in the generation of at least seven medical device manufacturing jobs in Southern California. Secondly, the proposal work will also create broader educational education opportunities through student internships in engineering, business development, and marketing. Students have already been recruited and several more have expressed interest in these opportunities. In addition, the effort will support local business offering legal and tax services, marketing and printing services, and supplier of manufacturing equipment and parts.